Amgen has ended development of its early-stage obesity drug AMG 513, foisting its hopes for a slice...
Amgen drops ph. 1 obesity drug, upping pressure on MariTide
Amgen has ended development of its early-stage obesity drug AMG 513, foisting its hopes for a slice of the massive weight loss market onto the shoulders of...
Author: Fierce Biotech
Read Original Article